Zacks Investment Research upgraded shares of BIO-TECHNE CP (TECH) from NEUTRAL to OUTPERFORM on January 19, 2015, with a target price of $97.50.
Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes antibodies, including polyclonal and monoclonal antibodies immunoassays comprising quantikine kits and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products natural and synthetic chemical compounds hematology controls and calibrators and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on BIO-TECHNE CP (TECH),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment